Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) has revealed its NNZ-2591 drug was well tolerated in healthy volunteers in a recent phase one trial
  • Over the course of seven days, 16 patients received either NNZ-2591 or a placebo twice daily to determine the safety and tolerability of the drug
  • Pleasingly, no serious adverse events were reported with drowsiness the most common adverse event reported
  • NNZ-2591 was manufactured to treat Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome
  • The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process
  • Despite this news, Neuren is down 2.11 per cent on the market and shares are trading at $1.40

Neuren Pharmaceuticals (NEU) has revealed its NNZ-2591 drug was well tolerated in healthy volunteers in a recent phase one trial.

This data will now form part of Neuren’s planned Investigational New Drug Applications to the U.S. Food and Drug Administration for phase two trials.

Over the course of seven days, 16 patients received either NNZ-2591 or a placebo twice daily to determine the safety and tolerability of the drug.

Testing was undertaken in two groups with one group receiving double the dose than the other.

Pleasingly, no serious adverse events were reported with drowsiness the most common side-effect reported.

Cardiac tests and neurological tests were also carried out but no significant findings were recorded.

All participants have now finished dosing apart from one who stopped due to moderate drowsiness and incoordination.

“This trial was the first human dosing for NNZ-2591 and we are very pleased with the outcome,” CEO Jon Pilcher said.

“Twice daily oral dosing for seven days was safe and well tolerated at doses we expect to be within the effective therapeutic range, which gives us confidence for dosing patients in our planned phase two trials,” he added.

NNZ-2591 was manufactured to be used against Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome.

These are all neurological disorders which are characterised by impaired connections and signalling between brain cells.

Symptoms usually include problems with motor skills, language, brain development, behaviour and seizures.

The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process.

Despite this news, Neuren is down 2.11 per cent on the market and shares are trading at $1.40 at 12:14 pm AEDT.

NEU by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.